L'inflammasome NLRP3 : physiopathologie et application thérapeutique

Translated title of the contribution: The NLRP3 inflammasome: Physiopathology and therapeutic application

Thomas Gicquel, Sacha Robert, Tatiana Victoni, Vincent Lagente

Research output: Contribution to journalShort surveypeer-review

7 Scopus citations


The innate immune system constitutes the first line of host defense against pathogens. “Nonself”, such as exogenous particles or pathogens, triggers an inflammatory response. Inflammasomes are molecular platforms activated upon cellular infection or stress that trigger the maturation of proinflammatory cytokines such as IL-1β. Activation of the NLRP3 inflammasome pathway, the most extensively studied, appears to be the corner stone of many inflammatory diseases, including Crohn's disease, rheumatoid arthritis and gout. Cryopyrine-associated periodic syndromes (CAPS) are NLRP3 inflammasome-associated diseases. Canakinumab (Ilaris®) is the only drug approved for CAPS treatment in France. Targeted therapy against NLRP3 inflammasome and IL-1β might be the new anti-inflammatory drugs.

Translated title of the contributionThe NLRP3 inflammasome: Physiopathology and therapeutic application
Original languageFrench
Pages (from-to)438-446
Number of pages9
JournalPresse Medicale
Issue number4
StatePublished - Apr 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Masson SAS


Dive into the research topics of 'The NLRP3 inflammasome: Physiopathology and therapeutic application'. Together they form a unique fingerprint.

Cite this